LENZ Therapeutics, Inc.
NASDAQ: LENZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Evert Schimmelpennink
- Employees
- 6
- Headquarters
- Solana Beach, United States
- IPO year
- 2024
- Market cap
- $175.0M
- Website
- https://www.lenz-tx.com
Loading LENZ…
Loading profile data…Frequently asked questions about LENZ
What does LENZ Therapeutics, Inc. (LENZ) do?
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III c...
Where does LENZ trade?
LENZ Therapeutics, Inc. (LENZ) trades on the NASDAQ Global Select.
What sector is LENZ in?
LENZ Therapeutics, Inc. (LENZ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of LENZ Therapeutics, Inc.?
Evert Schimmelpennink is the chief executive officer of LENZ Therapeutics, Inc. (LENZ).
Where is LENZ Therapeutics, Inc. headquartered?
LENZ Therapeutics, Inc. is headquartered in United States.
Does LENZ pay a dividend?
Yes — LENZ Therapeutics, Inc. (LENZ) paid a trailing twelve-month dividend of USD 7.21 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did LENZ go public?
LENZ Therapeutics, Inc. (LENZ) completed its initial public offering in 2024.